PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms

被引:3
|
作者
Bauer, Scott R. [1 ,2 ,3 ]
Breyer, Benjamin N. [2 ,4 ]
Oni-Orisan, Akinyemi [5 ,6 ]
Steinman, Michael A. [3 ,7 ]
Sim, Ida [1 ]
McCulloch, Charles E. [4 ]
Kenfield, Stacey A. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA
[3] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA USA
[6] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA
来源
关键词
randomized clinical trial design; personalized medicine; patient-reported outcomes; medication side effects; benign prostatic hyperplasia; deprescribing; & alpha; -antagonist; BENIGN PROSTATIC HYPERPLASIA; QUALITY-OF-LIFE; ALPHA-BLOCKER; MEN; DISCONTINUATION; VALIDATION; LUTS; FINASTERIDE; MEDICATION; MANAGEMENT;
D O I
10.3389/fdgth.2020.00007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Lower urinary tract symptoms (LUTS) affect more than half of men over age 70 and contribute to both poor health-related quality of life and polypharmacy. Tamsulosin hydrochloride, a selective a(1)-blocker, is the most common medication used to treat LUTS due to presumed benign prostatic hyperplasia and is often prescribed indefinitely, although not all men benefit from long-term therapy. N-of-1 trials allow for individualized estimates of benefit and harm and could facilitate decisions regarding chronic tamsulosin therapy for LUTS, particularly among older men. Our team developed the PERSONAL (PlacEbo-controlled, Randomized, patient-Selected Outcomes, N-of-1 triALs) app to track daily urinary symptoms and medication side effects for n-of-1 trials among older men with LUTS.Materials and Methods: We will conduct a feasibility study of 20 individual randomized n-of-1 trials using the PERSONAL app to compare tamsulosin (0.4 or 0.8 mg) vs. placebo among older men taking tamsulosin for LUTS. We will include men over age 65 with a smartphone for whom temporary discontinuation of tamsulosin is safe, (e.g., no history of acute retention). Participants will work with research staff to prospectively identify the most important urinary symptoms and medication side effects that they would like to digitally track. Men will then be randomized to 2-week treatment periods of tamsulosin or placebo followed by a 1-week wash-out with placebo, for 4 distinct treatment periods and 3 wash-out periods, totaling 11 weeks. Study medications will be blinded using over-encapsulation of tamsulosin pills and matching placebo. Our primary outcomes for this study will be recruitment and retention of eligible men, completion rates of n-of-1 trials and daily questionnaires using the PERSONAL app, and participants' perceived usefulness of their n-of-1 trial for determining whether tamsulosin is effective for them. Linear mixed effects models with individual-specific intercepts and intervention effects will also be used to estimate within-individual effects of tamsulosin.Discussion: The goal of this innovative study is to establish feasibility and acceptability of using a mobile health app and n-of-1 trials to provide older men with individualized estimates of benefits and harms of chronic tamsulosin therapy for LUTS.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] RANDOMIZED PLACEBO-CONTROLLED N-OF-1 TRIALS OF TAMSULOSIN FOR LOWER URINARY TRACT SYMPTOMS
    Li, Kevin
    Bauer, Scott
    Kenfield, Stacey
    Lu, Kaiwei
    McCulloch, Charles
    Steinman, Michael
    Oni-Orisan, Akinyemi
    Rios, Natalie
    Enriquez, Anthony
    Breyer, Benjamin
    JOURNAL OF UROLOGY, 2023, 209 : E318 - E319
  • [2] Placebo-controlled n-of-1 trials in cystic fibrosis
    Innes, JA
    Böllert, FGE
    EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (04) : 994 - 994
  • [3] A DOUBLE BLINDED, RANDOMIZED CONTROLLED TRIAL COMPARING TAMSULOSIN AND PLACEBO VERSUS TAMSULOSIN AND TADALAFIL IN MALE LOWER URINARY TRACT SYMPTOMS
    Nagasubramanian, Santhosh
    John, Nirmal Thampi
    Antonisamy, Belavendra
    Chandrasingh, J.
    Kumar, Santosh
    Devasia, Antony
    Kekre, Nitin Sudhakar
    JOURNAL OF UROLOGY, 2018, 199 (04): : E1140 - E1141
  • [4] EFFICACY OF TAMSULOSIN OCAS 0.4 MG IN FEMALE WITH LOWER URINARY TRACT SYMPTOMS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY
    Helmy, H.
    NEUROUROLOGY AND URODYNAMICS, 2012, 31 (06) : 811 - 811
  • [5] Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: Randomized, double-blind, placebo-controlled study
    MacDiarmid, Scott A.
    Peters, Kenneth M.
    Chen, Andrew
    Armstrong, Robert B.
    Orman, Camille
    Aquilina, Joseph W.
    Nitti, Victor W.
    MAYO CLINIC PROCEEDINGS, 2008, 83 (09) : 1002 - 1010
  • [6] Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo -controlled Study (MATCH)
    Kakizaki, Hidehiro
    Lee, Kyu-Sung
    Yamamoto, Osamu
    Jong, Jar Jar
    Katou, Daisuke
    Sumarsono, Budiwan
    Uno, Satoshi
    Yamaguchi, Osamu
    EUROPEAN UROLOGY FOCUS, 2020, 6 (04): : 729 - 737
  • [7] Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial
    Rommel Prata Regadas
    Ricardo Reges
    João Batista Gadelha Cerqueira
    Daniel Gabrielle Sucupira
    Iatagan Rocha Josino
    Emmanuel Almeida Nogueira
    Francisco Vagnaldo F. Jamacaru
    Manoel Odorico de Moraes
    Lúcio Flávio Gonzaga Silva
    International Urology and Nephrology, 2013, 45 : 39 - 43
  • [8] Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial
    Regadas, Rommel Prata
    Reges, Ricardo
    Gadelha Cerqueira, Joao Batista
    Sucupira, Daniel Gabrielle
    Josino, Iatagan Rocha
    Nogueira, Emmanuel Almeida
    Jamacaru, Francisco Vagnaldo F.
    de Moraes, Manoel Odorico
    Gonzaga Silva, Lucio Flavio
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2013, 45 (01) : 39 - 43
  • [9] Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial
    Nagasubramanian, Santhosh
    John, Nirmal Thampi
    Antonisamy, Belavendra
    Mukha, Rajiv Paul
    Berry, Chandra Singh Jeyachandra
    Kumar, Santosh
    Devasia, Antony
    Kekre, Nitin Sudhakar
    BJU INTERNATIONAL, 2020, 125 (05) : 718 - 724
  • [10] The design and analysis of randomized controlled trials of treatments for lower urinary tract symptoms
    Peters, TJ
    BJU INTERNATIONAL, 2000, 85 : 3 - 9